European Journal of Clinical Pharmacology

, Volume 40, Issue 4, pp 355–362 | Cite as

The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects

  • D. Allen
  • H. V. Curran
  • M. Lader
Originals

Summary

The effects of a 10 day administration of clomipramine (25–50 mg t.i.d.), alprazolam (0.25–0.75 mg t.i.d.) and placebo were assessed in normal volunteers in a double-blind cross-over study. A battery of physiological, psychomotor and cognitive tests was administered both before and 3 h after drug on days 1, 5 and 10.

The effects of alprazolam on EEG and evoked potentials were characteristic of benzodiazepines; clomipramine had little effect. In contrast, reaction speed was markedly slowed by clomipramine but little affected by alprazolam.

Neither drug produced any accumulation of effect on a verbal recall task but neither did tolerance develop to the acute impairments produced by active treatments. Alprazolam produced an increase in levels of forgetting, especially on day 5. Subjective ratings for mood and bodily symptoms were adversely affected by clomipramine but little altered by alprazolam.

It is suggested that some of the differences between drug treatments may be due to differences in the speed of onset of tolerance.

Key words

Clomipramine alprazolam psychomotor performance cognitive effects adverse effects healthy volunteers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander PE, Alexander DD (1986) Alprazolam treatment for panic disorders. J Clin Psychiatry 47: 301–304Google Scholar
  2. Aranko K, Mattila MJ, Bordignon D (1985) Psychomotor effects of alprazolam and diazepam during acute and subacute treatment and during the follow-up phase. Acta Pharmacol Toxicol 56: 364–372Google Scholar
  3. Baddeley AD, Sutherland A, Harris J (1982) How well do laboratory-based psychological tests predict patient's performance outside the laboratory? Aging 19: 141–148Google Scholar
  4. Ballenger JC, Burrows GD, DuPont RL, Lesser IM, Noyes R, Pecknold JC, Rifkin A, Swinson RP (1988) Alprazolam in panic disorders and agoraphobia: Results from a multicenter trial. 1. Efficacy in short-term treatment. Arch Gen Psychiatry 45: 413–422Google Scholar
  5. Bättig WF, Montague WE (1969) Category norms for verbal items in 56 categories: A replication and extension of the Connecticut Category Norms. J Exp Psychol 80: 1–46Google Scholar
  6. Block RI, Berchou R (1984) Alprazolam and lorazepam effects on memory acquisition and retrieval processes. Pharmacol Biochem Behav 20: 233–241Google Scholar
  7. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211–218Google Scholar
  8. Bond A, Lader M, Shrotriya R (1983) Comparative effects of a repeated dose regime of diazepam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharm 24: 463–467Google Scholar
  9. Branconnier RJ, Devitt DR, Cole JO, Spera KF (1982) Amitriptyline selectively disrupts verbal recall from secondary memory of the normal aged. Neurobiol Aging 3: 55–59Google Scholar
  10. Burrows GD, Norman TR (1981) Tricyclic antidepressants: Plasma levels and clinical response. In: Burrows GD, Norman TR (eds) Psychotropic drugs: Plasma concentration and clinical response. Dekker, New York, pp 169–205Google Scholar
  11. Chouinard G, Annable L, Fontaine R, Solyom L (1982) Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study. Psychopharmacology 77: 229–233Google Scholar
  12. Ciraulo DA, Barnhill JG, Boxenham HG, Greenblatt DJ, Smith RB (1986) Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorders. J Clin Pharmacol 26: 292–298Google Scholar
  13. Curran HV (1986) Tranquillizing memories: a review of the effects of benzodiazepines on human memory. Biol Psychol 23: 179–213Google Scholar
  14. Curran HV, Sakulsripong M, Lader M (1988) Antidepressants and human memory: an investigation of four drugs with different sedative and anticholinergic profiles. Psychopharmacology 95: 520–527Google Scholar
  15. Deutsch J (1971) The cholinergic synapse and the site of memory. Science 174: 788–794Google Scholar
  16. Drachman DA (1978) Central cholinergic system and memory. In: Lipton LA, DiMascio A, Killam KF (eds) Psychopharmacology, A generation of progress. Raven. New YorkGoogle Scholar
  17. Ghoneim MM, Mewaldt SP, Berie JL, Hinrichs JV (1981) Memory and performance effects of single and 3 week administration of diazepam. Psychopharmacology 73: 147–151Google Scholar
  18. Gloger S, Grunhaus L, Birmacher B, Troudhart T (1981) Treatment of spontaneous panic attacks with chlomipramine. Am J Psychiatry 138: 1215–1217Google Scholar
  19. Gloger S, Grunhaus L, Gladic D, O'Ryan F, Cohen L, Codner S (1989) Panic attacks and agoraphobia: Low dose clomipramine treatment. J Clin Psychopharm 9: 28–32Google Scholar
  20. Greenblatt DJ, Divoll M, Abernathy DR, Moschitto LJ, Smith RB, Shader RI (1983) Alprazolam kinetics in the elderly. Arch Gen Psychiatry 40: 287–290Google Scholar
  21. Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI (1988) Comparative single dose kinetics and dynamics of lorazepam, alprazolam, prazepam and placebo. Clin Pharmacol Ther 44: 326–333Google Scholar
  22. Kales A, Bixler EO, Vela-Bueno A, Soldatos CR, Manfredi RL (1987) Alprazolam: effects on sleep withdrawal phenomena. J Clin Pharmacol 27: 508–515Google Scholar
  23. Lamping DL, Spring B, Gelenberg AJ (1984) Effects of two antidepressants on memory performance in depressed outpatients: a double-blind study. Psychopharmacology 84: 254–261Google Scholar
  24. Lydiard RB, Ballenger JC (1987) Antidepressants in panic disorders and agoraphobia. J Affective Disord 13: 153–168Google Scholar
  25. McTavish D, Benfield P (1990) Clomipramine: An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs 39: 136–153Google Scholar
  26. Modigh K (1989) A treatment programme for panic disorder. In: Kielholz P, Adams C (eds) Panic anxiety states. Deutscher Ärzte-Verlag, KölnGoogle Scholar
  27. Noyes R, DuPont RL, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD (1988) Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. II Patient acceptance, side effects and safety. Arch Gen Psychiatry 45: 423–428Google Scholar
  28. Peck RE (1959) The SHP-test — an aid in the detection and measurement of depression. Arch Gen Psychiatry 1: 35–40Google Scholar
  29. Pecknold JC, Swinson RP, Kuch K, Lewis CP (1988) Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. III Discontinuation effects. Arch Gen Psychiatry 45: 429–436Google Scholar
  30. Roth T, Roehrs T, Wittig R, Zorick F (1984) Benzodiazepines and memory. Br J Clin Pharmacol 18: 45S-49SGoogle Scholar
  31. Smith RB, Kroboth PD (1987) Influence of dosing regimes on alprazolam and metabolic serum concentrations and tolerance to sedative and psychomotor effects. Psychopharm 93: 105–112Google Scholar
  32. Wechsler D (1955) Manual for the Wechsler Adult Intelligence Scale. Psychological Corporation, New YorkGoogle Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • D. Allen
    • 1
  • H. V. Curran
    • 1
  • M. Lader
    • 1
  1. 1.Department of PsychiatryInstitute of PsychiatryLondonUK

Personalised recommendations